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Abstract
Background: The purpose of the study was to examine serotonin, CD56, neurone-specific enolase (NSE), 
chromogranin A and synaptophysin by immunohistochemistry in renal cell carcinomas (RCCs) with special emphasis 
on patient outcome.
Methods: We studied 152 patients with primary RCCs who underwent surgery for the removal of kidney tumours 
between 1990 and 1999. The mean follow-up was 90 months. The expression of neuroendocrine (NE) markers was 
determined by immunohistochemical staining using commercially available monoclonal antibodies. Results were 
correlated with patient age, clinical stage, Fuhrman grade and patient outcome.
Results: Eight percent of tumours were positive for serotonin, 18% for CD56 and 48% for NSE. Chromogranin A 
immunostaining was negative and only 1% of the tumours were synaptophysin immunopositive. The NSE 
immunopositivity was more common in clear cell RCCs than in other subtypes (p = 0.01). The other NE markers did not 
show any association with the histological subtype. Tumours with an immunopositivity for serotonin had a longer RCC-
specific survival and tumours with an immunopositivity for CD56 and NSE had a shorter RCC-specific survival but the 
difference was not significant. There was no relationship between stage or Fuhrman grade and immunoreactivity for 
serotonin, CD56 and NSE.
Conclusions: Serotonin, CD56 and NSE but not synaptophysin and chromogranin A are expressed in RCCs. However, 
the prognostic potential of these markers remains obscure.
Background
Neuroendocrine (NE) cells are important for regulating
cell growth and differentiation. In addition to specific NE
tumours, NE activity can be detected in other types of
tumours such as breast [1] or prostate carcinomas [2].
The specific NE tumours of kidney include carcinoid, NE
carcinoma, primitive neuroectodermal tumour, neuro-
blastoma and phaeochromocytoma [3]. NE tumours can
show a wide range of behaviour. Small cell carcinomas of
the lung are aggressive [4], whereas carcinoid tumours
show indolent behaviour [5]. In patients with prostate
adenocarcinoma, NE differentiation has been linked to
both aggressive behaviour [6] and better survival [7].
Serotonin (5-hydroxytryptamine, 5HT) is a growth fac-
tor for several types of malignant cells. Serotonin causes
cellular proliferation [8], and there is also evidence link-
ing it to oncogenes [9]. By contrast, serotonin can also
inhibit tumour growth because of its vasoconstrictive
effect [10]. In RCC patients, plasma levels of serotonin
[11] and the immunoexpression for serotonin have previ-
ously been examined in patients with advanced disease
[12]. As far as we know, the prognostic significance of
serotonin expression in RCC patients has not been stud-
ied in large RCC patient material.
CD56 is neural cell adhesion molecule (NCAM), which
is also found in some lymphocytes [13]. In terms of clini-
cal pathology, CD56 is a rather sensitive indicator of NE
differentiation. The immunoexpression of CD56 has pre-
viously been studied in RCC and its prognostic potential
in the survival of RCC patients has also been evaluated
[14].
Neurone-specific enolase (NSE) is a broad-spectrum,
non-specific NE marker of all types of neurons, NE or
paraneuronal cells and even various malignant tumours
of non-NE types [15]. Its serum levels and immunoex-
pression have also been studied in RCCs [16,17,12].
* Correspondence: hanna.ronkainen@mail.suomi.net
1 Department of Surgery, PO Box 21, Oulu University Hospital, FIN-90029 Oulu, 
Finland
Full list of author information is available at the end of the articleRonkainen et al. Diagnostic Pathology 2010, 5:28
http://www.diagnosticpathology.org/content/5/1/28
Page 2 of 7
Chromogranin A is an abundant monomeric protein in
the neurosecretory granules of NE cells, and its immu-
nostaining correlates to the number of NE granules seen
at the level of electron microscopy [13]. The serum levels
and immunoexpression of chromogranin A have previ-
ously been studied in RCCs to evaluate its prognostic sig-
nificance [12,17].
Synaptophysin is regarded as one of the basic markers
o f  N E  d i f f e r e n t i a t i o n .  I t  i s  a n  i n t e g r a l  p a r t  o f  t h e  N E
secretory granule membrane [13]. To our knowledge, the
immunoexpression of synaptophysin has not previously
been studied in RCCs.
The aim of this study was to clarify the extent of the
immunoexpression of NE markers, serotonin, CD56,
NSE, chromogranin A and synaptophysin in RCCs and
their significance regarding the behaviour of these
tumours. For this we investigated a large set of RCCs con-
sisting of different histological types and correlated the
results with the clinical behaviour of the tumours.
Methods
The retrospective study group consisted of 152 patients
treated with radical nephrectomy or renal resection for
primary RCC at Oulu University Hospital, Oulu, Finland
between 1990 and 1999. Patients underwent medical
examination and preoperative staging including chest X-
ray and/or thoracic CT and abdominal CT. The research
plan was approved by the local ethics board. All the data
from the patients' records and Finnish Cancer Registry
were re-evaluated by the same urologist. The exact stage
of the disease was recorded according to the TNM classi-
fication of RCCs [18].
Archival material of formalin-fixed and paraffin-
embedded tumours were reclassified and graded accord-
ing to current WHO classification [3]. The most repre-
sentative area from each tumour block was selected to a
multitissue array block. The array section was 3 μm thick.
Immunostaining procedure
The antibodies used in the immunostaining were mono-
clonal mouse anti-human serotonin (DakoCytomation,
Glostrup, Denmark) in a dilution of 1:200, lyophilized
mouse monoclonal antibody for CD56 (Novocastra Lab-
oratories Ltd., Newcastle-upon-Tyne, UK) in a dilution of
1:200, monoclonal mouse anti-NSE (Zymed Laboratories,
Carlsbad, CA, USA) in a dilution 1:1000, polyclonal rab-
bit anti-chromogranin A (Zymed Laboratories, Carlsbad,
CA, USA) in a dilution 1:500 and monoclonal mouse
anti-synaptophysin (DakoCytomation) in a dilution 1:50.
First, the sections were deparaffinised in xylene, rehy-
drated in descending ethanol series and washed in phos-
phate-buffered saline (PBS). Then, the sections were
boiled in 0.01 M citrate buffer (pH 6) for 10 min (sero-
tonin and CD56) or Tris/EDTA for 15 min (chromogra-
nin A and synaptophysin) in a microwave oven. The
sections were cooled for 15 min and washed twice in PBS.
Endogenous peroxidise activity was eliminated by incu-
bation in 5% hydrogen peroxide and absolute methanol.
Bound antibodies were visualised using an UltraVision
(Thermo Fisher Scientific, Fremont, CA, USA) for sero-
tonin, CD56 and NSE and EnVision (DakoCytomation)
for chromogranin A and synaptophysin. DAB (5% 3,3'-
diaminobenzidine tetrahydrochloride, DakoCytomation)
was used as the chromogen. The positive controls for
stainings were the metastasis of neuroendocrine tumour
for serotonin, small cell carcinoma for CD56 and NSE,
and colonic mucosa for chromogranin A and synapto-
physin. PBS instead of primary antibody was used as a
negative control.
Immunohistochemical evaluation of NE markers
Cytoplasmic immunostaining for serotonin, CD56, NSE,
chromogranin A and synaptophysin was classified
dichotomously as positive or negative simultaneously by
three observers (HR, PH and SK).
Statistical analyses
SPSS for Windows 15 (Chicago, IL, USA) was used for
statistical analyses. Statistical significance between stain-
ings and clinicopathological parameters was determined
using the chi-squared test or Fisher's exact test in the case
of low expected frequencies. Corrected cancer-specific
survival was analysed with the Kaplan-Meier curve and
the significance with the log rank test. The Cox regres-
sion model was used for multivariate analysis.
Results
Patients, follow-up and treatment
The median age of the patients was 63 (range 29-86)
years. Seventy-seven (51%) patients were women, 75
(49%) men. Seven tumours (5%) were resected and 145
(95%) were operated by radical nephrectomy. The median
follow-up time was 90 (range 0-209) months and follow-
up was complete in all cases. During follow-up, 44 (29%)
patients died of RCC, 40 (26%) died of other causes and
68 (45%) patients were still alive. The distribution of clin-
icopathological parameters of the tumours is described in
Table 1.
Immunohistochemical findings
Twelve tumours (8%) were stained for serotonin and 26
(18%) for CD56. The immunopositivity for NSE was
detected in 69 cases (48%). The immunopositivity for
serotonin and CD56 were detected in the same tumours
(p < 0.001). All tumours were immunonegative for chro-
mogranin A (100%). Two of the tumours (1%) were
immunopositive for synaptophysin.
The immunopositivity for NSE was more common in
clear cell RCCs than other subtypes (p = 0.01). There wasRonkainen et al. Diagnostic Pathology 2010, 5:28
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no association between the immunoreactivity for other
NE markers and histological subtype of the tumours
(Table 2).
The RCC-specific survival of patients with serotonin
positive tumours (Figure 1) as well as CD56 and NSE
immunonegative tumours was somewhat better but the
difference was not significant (Table 3). The two patients
with synaptophysin immunopositive tumours showed an
excellent RCC-specific survival.
Immunostaining for serotonin, CD56 and NSE did not
associate with grade or stage (Table 4). Each staining
(serotonin, CD56 and NSE) was separately included in
the Cox multivariate analysis with stage, Fuhrman grade
and age. The only significant prognostic factor for RCC-
specific survival was stage (p < 0.001).
Discussion
Evidence regarding the prognostic influence of NE mark-
ers in human carcinomas is confusing. For example, in
prostate cancer both the increased and decreased immu-
noexpression of NE marker serotonin have been associ-
a t e d  w i t h  a d v a n c e d  o r  a g g r e s s i v e  d i s e a s e  [ 6 , 7 ] .  I n
undifferentiated endometrial carcinomas, NE markers
had no prognostic significance [19]. In addition, the clini-
cal behaviour of breast carcinomas with NE differentia-
tion is not well established [20]. The current paper
examines the expression of NE markers (serotonin,
CD56, chromogranin A, synaptophysin and NSE) in RCC
with a special reference for patient survival.
Serotonin is a monoamine neurotransmitter mediating
a wide range of physiological actions in the human body.
Among others it is implicated in psychiatric and neuro-
logical disorders and also plays a fundamental role in
tumour growth, differentiation and gene expression [8].
Serotonin has been proposed to take part in the autocrine
loops of growth factors, contributing to cell proliferation
in aggressive tumours such as small cell lung carcinoma.
By contrast, serotonin can inhibit tumour growth, which
is thought to be related to its vasoconstrictive effect [10].
It has been shown that decreased serotonin immunoex-
pression is associated with the progression of prostate
cancer [7]. Furthermore, serotonin receptor overexpres-
sion is demonstrated in high-grade tumours and sero-
tonin seems to stimulate prostate cancer cells [6]. In RCC,
it has been shown that plasma serotonin levels are
decreased in patients with metastases but there was no
significant association between plasma serotonin level
and the extent of the disease [11]. In a previous study of
10 patients with advanced RCC, no immunoexpression of
serotonin was detected [12]. In the current study, the
immunostaining for serotonin was uncommon, and only
8% of tumours were serotonin immunopositive. The dis-
crepancy in detected immunoexpression with the earlier
study [12] might be because of different stage groups and
a larger study population. The immunoreactivity for sero-
tonin was detected only in localised or locally advanced
disease. None of the tumours with distal metastases were
immunopositive for serotonin. However, in terms of
patient survival, the immunohistochemical expression of
serotonin in RCC seems to have no clinical significance.
CD56 is a member of the immunoglobulin superfamily.
Only 15% of conventional RCCs express CD56 and the
positivity is associated with poor patient outcome [14]. In
addition, the expression of CD56 has been associated
with a higher risk of adrenal gland and central nervous
system metastases, tumour size, renal vein involvement,
perirenal invasion and aggressive Fuhrman grade [14]
The current data, however, did not support this observa-
tion (data not shown). In our study, there was immunos-
taining for CD56 in 18% of clear cell RCCs, which is
consistent with the earlier study. However, the same fre-
quency of CD56 positivity in papillary and chromophobic
RCCs was also detected. The expression of CD56 was not
associated with stage or grade. Despite a shorter mean
survival for CD56 positive tumours, the expression of
Table 1: Distribution of clinical stages and T classes, 
nuclear grade and histological evaluation.
n (%)
Clinical stage
I 70 (46)
II 12 (8)
III 51 (34)
IV 19 (12)
Tumour class
T1 75 (49)
T2 12 (8)
T3 59 (39)
T4 6 (4)
Nuclear grade
grade I 5 (3)
grade II 83 (55)
grade III 40 (27)
grade IV 22 (15)
Histological subtype
clear cell 134 (88.2)
papillary 11 (7.2)
chromophobic 5 (3.3)
unclassified 2 (1.3)Ronkainen et al. Diagnostic Pathology 2010, 5:28
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CD56 was not a significant predictive marker for RCC in
the current study.
NSE is a rather non-specific marker of NE differentia-
tion, which can be found in a variety of normal and neo-
plastic NE cells as well as in any type of neoplasms even
of non-NE origin [15,13]. Elevated serum NSE levels can
be detected in 27-80% of patients with RCC [16,17] and
seem to be associated with patient outcome [17]. After
the treatment of RCC, serum levels of NSE decrease and
it has been suggested that this could be a useful marker in
the surveillance of RCC [16]. The immunoreactivity for
NSE in RCC has been found to be up to 100% [12,17]. In
our study, half of tumours were immunopositive for NSE.
The immunoreactivity for NSE did not associate with
stage or grade. Positivity for NSE was more common in
clear cell carcinomas than other subtypes of RCCs.
Immunostaining for NSE was not a prognostic factor in
RCC-specific survival. In our study population, the
expression of NSE was not as common as in previous
studies and did not show any prognostic significance in
RCC.
Chromogranin A was originally identified as a major
soluble protein in adrenal medullary chromaffin granules
many decades ago [21]. It has been intensively studied
with respect of its physiological role and pathological
expression in tumours [22]. In a previous study, serum
Table 2: Association between immunoreactivity for NE markers and histological subtype of RCC.
Immunoreactivity
Histological subtype Marker negative, n (%) positive, n (%) p-value
clear cell serotonin 121 (93) 9 (7) 0.2
papillary 6 (75) 2 (25)
chromophobic 4 (80) 1 (20)
unclassified 2 (100) 0 (0)
clear cell CD56 105 (82) 23 (18) 0.9
papillary 7 (78) 2 (22)
chromophobic 4 (80) 1 (20)
unclassified 2 (100) 0 (0)
clear cell NSE 62 (48) 67 (52) 0.01
papillary 8 (80) 2 (20)
chromophobic 4 (100) 0 (0)
unclassified 2 (100) 0 (0)
clear cell synaptophysin 130 (99) 1 (1) 0.2
papillary 9 (90) 1 (10)
chromophobic 5 (100) 0 (0)
unclassified 2 (100) 0 (0)
Table 3: RCC-specific mean survivals for serotonin, CD56 and NSE.
Marker Immunoreactivity Survival, months (95% CI) p-value
serotonin positive 176 (138-214) 0.3
negative 148 (133-163)
CD56 positive 139 (106-172) 0.4
negative 156 (140-172)
NSE positive 149 (127-171) 0.8
negative 153 (134-171)
CI, confidence interval.Ronkainen et al. Diagnostic Pathology 2010, 5:28
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chromogranin A was found to be elevated in 14% of RCC
patients without any prognostic significance in RCC [17].
The immunohistochemical reactivity for chromogranin
A has been detected in 4% of RCC patients [17] or the
tumours have been wholly immunonegative for chro-
mogranin A [12]. In our study, we found no immunoreac-
tivity for chromogranin A in RCCs, which is consistent
with the latter study.
Synaptophysin is a transmembrane glycoprotein of pre-
synaptic vesicles of nerve endings [23,24]. It is regarded
as one of the most specific markers of NE differentiation.
The immunoexpression of synaptophysin has previously
been described in undifferentiated endometrial carcino-
mas where it did not seem to have a significant prognos-
tic potential [19]. To our knowledge, this is the first study
describing the immunostaining of synaptophysin in RCC.
In our study, immunostaining for synaptophysin was rare
(only 1% of the tumours). Interestingly, the prognosis of
patients with synaptophysin immunopositive tumours
was excellent. Both patients whose primary RCC tumour
showed an immunopositivity for synaptophysin are still
alive after 10 and 17 years follow-up. The TNM classes
for these synaptophysin immunopositive tumours were
pT1aN0M0 and pT3aN0M0. Synaptophysin positivity in
RCC may be associated with good prognosis, but as an
uncommon phenomenon, this observation should be fur-
ther studied with large number of RCC tumours.
Conclusions
To conclude, the immunohistochemical expression of NE
markers was quite common in RCC. The current study
showed that serotonin, CD56, chromogranin A, synapto-
physin and NSE were not potential prognostic markers in
RCCs. The outcome of an individual patient with RCC is
still to be evaluated with traditional clinicopathological
markers such as stage and grade.
Figure 1 Cytoplasmic serotonin as a prognostic factor in RCC-specific survival. Kaplan-Meier curve of 145 patients (p = 0.3).Ronkainen et al. Diagnostic Pathology 2010, 5:28
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